References

 

  1. New York City Department of Health and Mental Hygiene. HIV surveillance annual report, 2014. https://www1.nyc.gov/assets/doh/downloads/pdf/dires/2014-hiv-surveillance-annual-report.pdf. Accessed on September 13, 2016
  2. New York City Department of Health and Mental Hygiene. Bureau of Sexually Transmitted Disease Control quarterly report (2014: 4th quarter). http://www.nyc.gov/html/doh/downloads/pdf/std/std-quarterlyreport2014-4.pdf. Accessed on March 8, 2016
  3. Pathela P, Braunstein SL, Blank S, Shepard C, Schillinger JA. The high risk of an HIV diagnosis following a diagnosis of syphilis: a population-level analysis of New York City men. Clin Infect Dis. 2015;61(2):281-287.
  4. Pathela P, Braunstein SL, Blank S, Schillinger JA. HIV incidence among men with and those without sexually transmitted rectal infections: estimates from matching against an HIV case registry. Clin Infect Dis. 2013;57(8):1203-1209.
  5. Centers for Disease Control and Prevention. HIV among gay and bisexual men. http://www.cdc.gov/hiv/group/msm/. Accessed on September 9, 2016
  6. Hess K, Hu X, Lansky A, Mermin J, Hall HI. Estimating the lifetime risk of a diagnosis of HIV infection in the United States [CROI Abstract 52]. In Special Issue: Abstracts From the 2016 Conference on Retroviruses and Opportunistic Infections. Top Antivir Med. 2016;24(e-1):24.
  7. Nuttbrock L, Hwahng S, Bockting W, et al. Lifetime risk factors for HIV/sexually transmitted infections among male-to-female transgender persons. JAIDS. 2009;52(3):417-421.
  8. Schuster MA, Reisner SL, Onorato SE. Beyond bathrooms-meeting the health needs of transgender people. New England Journal of Medicine. 2016;375(2):101-103.
  9. New York City Department of Health and Mental Hygiene. HIV/AIDS in New York City, 2010-2014. http://www1.nyc.gov/assets/doh/downloads/pdf/dires/hiv-aids-overall.pdf. Accessed on September 13, 2016
  10. New York City Department of Health and Mental Hygiene. Care and clinical status of people newly diagnosed with HIV and people living with HIV/AIDS in NYC, 2014. http://www1.nyc.gov/assets/doh/downloads/pdf/dires/hiv-related-medical-care.pdf. Accessed on September 13, 2016
  11. AIDS.gov. HIV/AIDS care continuum. https://www.aids.gov/federal-resources/policies/care-continuum/. Accessed on September 12, 2016
  12. NYC Mayor’s Office of Operations. Mayor’s management report (MMR). http://www1.nyc.gov/site/operations/performance/mmr.page. Accessed on September 13, 2016
  13. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. New England Journal of Medicine. 2011;365(6):493-505.
  14. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. New England Journal of Medicine. 2010;363(27):2587-2599.
  15. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. New England Journal of Medicine. 2012;367(5):399-410.
  16. Volk JE, Marcus JL, Phengrasamy T, et al. No new HIV infections with increasing use of HIV preexposure prophylaxis in a clinical practice setting. Clin Infect Dis. 2015;61(10):1601-1603.
  17. Smith DK, Herbst JH, Zhang X, Rose CE. Condom effectiveness for HIV prevention by consistency of use among men who have sex with men in the United States. JAIDS. 2015;68(3):337-344.
  18. New York State Department of Health. Blueprint for achieving the goal set forth by Governor Cuomo to end the epidemic in New York State by the end of 2020. http://www.health.ny.gov/diseases/aids/ending_the_epidemic/docs/blueprint.pdf. Accessed on March 9, 2016
  19. Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64(RR-03):1-137.
  20. Bernstein KT, Stephens SC, Barry PM, et al. Chlamydia trachomatis and Neisseria gonorrhoeae transmission from the oropharynx to the urethra among men who have sex with men. Clin Infect Dis. 2009;49(12):1793-1797.
  21. New York State Department of Health AIDS Institute. Update: HIV prophylaxis following non-occupational exposure. http://www.hivguidelines.org/clinical-guidelines/post-exposure-prophylaxis/hiv-prophylaxis-following-non-occupational-exposure/. Accessed on March 9, 2016
  22. Kuhar DT, Henderson DK, Struble KA, et al. Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Infect Control Hosp Epidemiol. 2013;34(9):875-892.
  23. Heuker J, Sonder GJ, Stolte I, Geskus R, van den Hoek A. High HIV incidence among MSM prescribed postexposure prophylaxis, 2000-2009: indications for ongoing sexual risk behaviour. AIDS. 2012;26(4):505-512.
  24. Liegler T, Abdel-Mohsen M, Bentley LG, et al. HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial. J Infect Dis. 2014;210(8):1217-1227.
  25. Lehman DA, Baeten JM, McCoy CO, et al. Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis. J Infect Dis. 2015;211(8):1211-1218.
  26. Smith DK, Grohskopf LA, Black RJ, et al. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. MMWR Recomm Rep. 2005;54(RR-2):1-20.
  27. New York State Department of Health AIDS Institute. Guidance for the use of pre-exposure prophylaxis (PrEP) to prevent HIV transmission. http://www.hivguidelines.org/clinical-guidelines/pre-exposure-prophylaxis/guidance-for-the-use-of-pre-exposure-prophylaxis-prep-to-prevent-hiv-transmission/. Accessed on March 9, 2016
  28. Papp JR, Schachter J, Gaydos CA, Van Der Pol B. Recommendations for the laboratory-based detection of chlamydia trachomatis and Neisseria gonorrhoeae — 2014. MMWR Recomm Rep. 2014;63(RR-02):1-19.
  29. Marcus JL, Bernstein KT, Kohn RP, Liska S, Philip SS. Infections missed by urethral-only screening for chlamydia or gonorrhea detection among men who have sex with men. Sex Transm Dis. 2011;38(10):922-924.
  30. Kent CK, Chaw JK, Wong W, et al. Prevalence of rectal, urethral, and pharyngeal chlamydia and gonorrhea detected in 2 clinical settings among men who have sex with men: San Francisco, California, 2003. Clin Infect Dis. 2005;41(1):67-74.
  31. Newman LM, Moran JS, Workowski KA. Update on the management of gonorrhea in adults in the United States. Clin Infect Dis. 2007;44(Suppl 3):S84-S101.
  32. Soge OO, Harger D, Schafer S, et al. Emergence of increased azithromycin resistance during unsuccessful treatment of Neisseria gonorrhoeae infection with azithromycin (Portland, OR, 2011). Sex Transm Dis. 2012;39(11):877-879.
  33. Waters LJ, Boag FC, Betournay R. Efficacy of azithromycin 1 g single dose in the management of uncomplicated gonorrhoea. Int J STD AIDS. 2005;16(1):84.
  34. McLean CA, Wang SA, Hoff GL, et al. The emergence of Neisseria gonorrhoeae with decreased susceptibility to azithromycin in Kansas City, Missouri, 1999 to 2000. Sex Transm Dis. 2004;31(2):73-78.
  35. Chisholm SA, Neal TJ, Alawattegama AB, Birley HD, Howe RA, Ison CA. Emergence of high-level azithromycin resistance in Neisseria gonorrhoeae in England and Wales. J Antimicrob Chemother. 2009;64(2):353-358.
  36. Woolston S, Cohen SE, Fanfair RN, Lewis SC, Marra CM, Golden MR. A cluster of ocular syphilis cases – Seattle, Washington, and San Francisco, California, 2014-2015. MMWR Morb Mortal Wkly Rep. 2015;64(40):1150-1151.
  37. Riedner G, Rusizoka M, Todd J, et al. Single-dose azithromycin versus penicillin G benzathine for the treatment of early syphilis. New England Journal of Medicine. 2005;353(12):1236-1244.
  38. Katz KA, Klausner JD. Azithromycin resistance in Treponema pallidum. Curr Opin Infect Dis. 2008;21(1):83-91.
  39. Centers for Disease Control and Prevention. Azithromycin treatment failures in syphilis infections–San Francisco, California, 2002-2003. MMWR Morb Mortal Wkly Rep. 2004;53(9):197-198.
  40. Centers for Disease Control and Prevention. Preexposure prophylaxis for the prevention of HIV infection in the United States – 2014: a clinical practice guideline. http://www.cdc.gov/hiv/pdf/guidelines/PrEPguidelines2014.pdf. Accessed on August 26, 2016
  41. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed on September 15, 2016
  42. Gunthard HF, Saag MS, Benson CA, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society-USA panel. JAMA. 2016;316(2):191-210.
  43. Lundgren JD, Babiker AG, Gordin F, et al. Initiation of antiretroviral therapy in early asymptomatic HIV Infection. New England Journal of Medicine. 2015;373(9):795-807.
  44. Frieden TR, Das-Douglas M, Kellerman SE, Henning KJ. Applying public health principles to the HIV epidemic. New England Journal of Medicine. 2005;353(22):2397-2402.
  45. Cohen M, Chen Y, McCauley M et al. Final results of the HPTN 052 randomized controlled trial: antiretroviral therapy prevents HIV transmission [Abstract MOAC0101LB]. 8th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment, and Prevention. July 19-22, 2015; Vancouver, Canada
  46. Pilcher C, Hatano H, Dasgupta A et al. Providing same day, observed ART to newly diagnosed HIV+ outpatients is associated with improved virologic suppression [Abstract WEAD0105 LB]. 8th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment, and Prevention. July 19-22, 2015; Vancouver, Canada
  47. Stekler JD, McKernan J, Milne R, et al. Lack of resistance to integrase inhibitors among antiretroviral-naive subjects with primary HIV-1 infection, 2007-2013. Antivir Ther. 2015;20(1):77-80.
  48. Bernstein KT, Marcus JL, Nieri G, Philip SS, Klausner JD. Rectal gonorrhea and chlamydia reinfection is associated with increased risk of HIV seroconversion. JAIDS. 2010;53(4):537-543.